Effects of Percutaneous Platelet-Rich Plasma Injection on Return-to-Play After Acute Hamstring Muscle Injury: A Systematic Review and Meta-Analysis

Why It Matters

An eight‑day reduction in recovery can provide a competitive edge for elite teams, while the safety profile supports broader clinical consideration. However, methodological variability underscores the need for standardized PRP protocols before widespread adoption.

Key Takeaways

• PRP cuts RTP by ~8.6 days.
• Six RCTs, 277 athletes analyzed.
• Reinjury rates unchanged between PRP and control.
• Evidence rated low‑to‑moderate due to bias.
• Image‑guided injections yield strongest RTP reduction.

Pulse Analysis

Platelet‑rich plasma (PRP) has become a popular biologic therapy for musculoskeletal injuries, promising accelerated healing through concentrated growth factors. In elite sport, hamstring strains are a leading cause of missed training and competition, prompting clinicians to explore regenerative options. The 2026 British Journal of Sports Medicine meta‑analysis pooled six randomized controlled trials, representing 277 athletes, to quantify PRP’s effect on return‑to‑play (RTP) after acute hamstring tears. By synthesising data across orthopaedic and sports‑medicine centres, the review offers the most comprehensive efficacy snapshot to date and highlights gaps in standardizing PRP protocols across studies.

The pooled results showed an average RTP reduction of 8.6 days, shrinking typical recovery from 30 to roughly 21 days. Although statistically significant (p = 0.045), heterogeneity was extreme (I² = 94 %), reflecting variations in injection timing, PRP preparation, and imaging guidance. Safety signals remained negligible, with a single adverse event reported and no difference in reinjury rates (15 % vs 16 %). Nonetheless, the GRADE assessment downgraded confidence to low‑to‑moderate because of risk‑of‑bias concerns and imprecise effect estimates.

For professional teams and athletic trainers, an eight‑day acceleration can translate into crucial competitive advantage, especially during congested seasons. However, the high methodological variability cautions against blanket adoption; clinicians should prioritize image‑guided protocols and adhere to standardized PRP processing to replicate trial conditions. The findings also signal a market opportunity for biotech firms to develop validated PRP kits tailored to muscle injuries. Future large‑scale, double‑blind trials are needed to confirm efficacy, define optimal dosing, and establish long‑term outcomes, which will ultimately shape reimbursement policies and clinical guidelines.